486 related articles for article (PubMed ID: 21353644)
1. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
2. IgG replacement therapy, no size fits all.
Bonilla FA
Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
[No Abstract] [Full Text] [Related]
3. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
Berger M
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
5. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
Jolles S; Sleasman JW
Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
8. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
10. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
Shapiro R
Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
[TBL] [Abstract][Full Text] [Related]
12. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
13. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.
Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G;
Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients.
Shankar T; Gribowicz J; Crespo M; Silveira FP; Pilewski J; Petrov AA
Int Immunopharmacol; 2013 Apr; 15(4):752-5. PubMed ID: 23499641
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of IgG administered by the subcutaneous route.
Berger M; Jolles S; Orange JS; Sleasman JW
J Clin Immunol; 2013 Jul; 33(5):984-90. PubMed ID: 23456255
[TBL] [Abstract][Full Text] [Related]
17. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Li Z; McCoy B; Engl W; Yel L
J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
[TBL] [Abstract][Full Text] [Related]
18. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
